SAN DIEGO, Aug.  07, 2026  (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether CVRx, Inc. (NASDAQ:CVRX) or certain of its executive officers violated state or federal securities laws. The investigation

CVRX

CVRx, Inc. (CVRX) Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel Following Revenue Guidance Cut and Sales-Execution Disclosures

CVRx Faces Revenue Downgrade and DOJ Inquiry, Upending Near-Term Outlook

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>SAN DIEGO, Aug.  07, 2026  (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether CVRx, Inc. (NASDAQ:CVRX) or certain of its executive officers violated state or federal securities laws. The investigation</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>CVRx trimmed its 2026 revenue guidance to $58–$60M from $63–$67M, citing onboarding strain and turnover. The company also disclosed a DOJ civil investigative demand over sales and marketing practices, complicating the outlook as roughly half of regions show negative implant growth and a Medicare Advantage payer dispute persists. This combination of execution risk and regulatory scrutiny could weigh on shares in the near term unless management provides clarity.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>CVRx cuts 2026 revenue guidance to $58M–$60M; cites onboarding strain. Hiring churn cited as primary cause.</li><li>DOJ civil investigative demand in May 2026; focus on CVRx sales/marketing practices. Company disclosed ongoing probe.</li><li>About half of regions show negative year-to-date implant growth; turnover drives the trend.</li><li>Johnson Fistel investigating CVRx executives for misrepresentation or delayed disclosures; regulatory risk noted.</li><li>Near-term CVRx stock may react to guidance downgrade and DOJ developments.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>CVRx, Inc. (CVRX)</strong>: Subject of revenue downgrade and regulatory inquiry; immediate stock risk from new disclosures.</li><li><strong>Johnson Fistel, PLLP (N/A)</strong>: Investigating CVRx for potential securities-law violations; increases investor attention and risk of forthcoming disclosures.</li><li><strong>U.S. Department of Justice (N/A)</strong>: Civil investigative demand in May 2026 indicates formal regulatory scrutiny of CVRx practices.</li></ul>
  </section>

  <section data-block="category">
    <h3>Legal</h3>
    <p>Category: Legal. The piece centers on regulatory scrutiny and a securities investigation alongside a corporate earnings guidance update, shaping CVRX&#039;s risk profile and near-term valuation more than core operating fundamentals.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Guidance downgrade to $58–$60M pressures near-term valuation.</li><li>DOJ civil investigative demand adds regulatory risk and potential penalties.</li><li>Regional execution risk from turnover drives uneven implant growth.</li><li>Medicare Advantage payer challenges could affect reimbursements.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Aug 6, 2026: CVRx lowers full-year revenue guidance to $58M–$60M from $63M–$67M.</li><li>Guidance cited rapid hiring causing onboarding strain and slower territory productivity ramp.</li><li>Slightly less than half of CVRx regions showing negative year-to-date implant growth.</li><li>Prolonged challenge with one of CVRx&#039;s largest Medicare Advantage payers mentioned.</li><li>May 2026: DOJ civil investigative demand related to CVRx sales and marketing practices.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Near-term pressure on CVRX shares ahead of clarity on the DOJ inquiry and updated guidance.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p>SAN DIEGO, Aug.  07, 2026  (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether CVRx, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/CVRX">CVRX</a>) or certain of its executive officers violated state or federal securities laws. The investigation focuses on investors’ losses and whether they may be recovered under federal securities laws.</p>  <p><strong>What if I purchased CVRx securities?</strong><br></br>If you purchased CVRx securities and suffered losses on your investment, you may join our investigation now:</p>  <p>Click Here to Join the Investigation: <a href="https://www.globenewswire.com/Tracker?data=NjSzZSqguhLDavMHfhtmLDzWj5mjtJ3PRnYqj5UnT8DWc2sC2xRiiyfgn-1qY9QMko8p1Sz9hZkBOi_v9xwCZHtT6k4UXIwdstIPQvJTwAsQoOOaOq5368cl9ftxtdWWE7zNHEEgbjxoRJg7pfWwM6eZjwDyz27Ia4mhsFr-opM=" rel="nofollow" target="_blank">https://www.johnsonfistel.com/investigations/cvrx/</a></p>  <p>Or for more information, contact James Baker at <a href="https://www.globenewswire.com/Tracker?data=efo7U24BxTnOs75-jIbEyEtKMPDJ_L7smo-yJPw5OUvmL1zmvcjGaphldLmo17K6ot0vd4B_8bC7YBxPJzM_HjvDpHlkq21lWQDQVm8Dn8U=" rel="nofollow" target="_blank">jimb@johnsonfistel.com</a> or (619) 814-4471.</p>  <p>There is no cost or obligation to you.</p>  <p><strong>What Is Johnson Fistel Investigating?</strong><br></br>On August 6, 2026, CVRx lowered its full-year revenue guidance to $58 million–$60 million from $63 million–$67 million. Management stated: "This rapid pace of hiring has strained our onboarding and training processes and the ability of our area sales directors to spend the time necessary to accelerate these new team members up the productivity curve." Management further stated: "The scale of the turnover, the slower pace of the territory manager productivity ramp, and the concentration of these new hires in a subset of our regions are the primary factors behind today’s guidance update."</p>  <p>Management also stated that slightly less than half of CVRx’s regions, those with the highest turnover and least-tenured leaders, were experiencing negative year-to-date implant growth. CVRx also attributed its revised outlook in part to a prolonged challenge with one of its largest Medicare Advantage payers. The Company further disclosed that it received a Department of Justice civil investigative demand in May 2026 concerning certain sales and marketing practices.</p>  <p>Johnson Fistel is investigating whether CVRx or certain executives misrepresented or failed to timely disclose material information concerning sales-force execution, onboarding, reimbursement challenges, and the Company’s 2026 revenue outlook.</p>  <p><strong>About Johnson Fistel, PLLP</strong><br></br>Johnson Fistel, PLLP is a nationally recognized shareholder-rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in securities class actions and shareholder derivative litigation and also assists foreign investors who purchased securities on U.S. exchanges. To learn more, visit <a href="https://www.globenewswire.com/Tracker?data=JjOyvC1A2_pvajBl3JwzplvKAsoBAvh-yRQjFRkmyUMedB2MruoePpbMC1bTqX3jy11ABC1J1pdvHG5XMB0-ZhsA5LEzPLm_Xh8chB38JDo=" rel="nofollow" target="_blank">www.johnsonfistel.com</a>.</p>  <p><strong>Achievements</strong><br></br>In 2024, Johnson Fistel was ranked among the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services, reflecting the firm’s effectiveness in advocating for investors and recovering approximately $90,725,000 for clients in cases in which it served as lead or co-lead counsel.</p>  <p>Attorney advertising.<br></br>Past results do not guarantee future outcomes.<br></br>Services may be performed by attorneys in any of our offices.<br></br>Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.</p>  <p><strong>Contact:</strong><br></br>Johnson Fistel, PLLP<br></br>501 W. Broadway, Suite 800<br></br>San Diego, CA 92101<br></br>James Baker, Investor Relations – or – Frank J. Johnson, Esq.<br></br>(619) 814-4471<br></br><a href="https://www.globenewswire.com/Tracker?data=efo7U24BxTnOs75-jIbEyEtKMPDJ_L7smo-yJPw5OUsdckozD-C2D7r4CnYWXdRpSq4vGbXNkX0paxAL74BIz3hiBfQwcQiThB_TypwvrXQ=" rel="nofollow" target="_blank">jimb@johnsonfistel.com</a> &#x7C; <a href="https://www.globenewswire.com/Tracker?data=leC_wEnylvTnv_eVcRuGONMeqs7fezxbQJgtdYXULTnvuCMR8RmSM0JJtUpTLDM5z66VwRo12kvh42zwWqfuM87OfwlCMYOM_s-xmpK6wf81rNOUKZiYAvifoTh5w66U" rel="nofollow" target="_blank">fjohnson@johnsonfistel.com</a></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTgwNjA3MSM3NzY1MzIwIzIxODE3ODk="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/MDFkOGQyMjAtZDU2NS00ZjE5LTlhM2ItMjg4ZjRiMDE0ZDE5LTExOTMzNTgtMjAyNi0wOC0wNy1lbg==/tiny/Johnson-Fistel-PLLP.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/bb2e6cf6-9d53-4d2e-a5d2-759cdd3b516c"><img src="https://ml.globenewswire.com/media/bb2e6cf6-9d53-4d2e-a5d2-759cdd3b516c/small/johnson-fistel-jpg.jpg" border="0" width="150" height="150" alt="Primary Logo"></img></a></p>

CVRx trimmed its 2026 revenue guidance to $58–$60M from $63–$67M, citing onboarding strain and turnover. The company also disclosed a DOJ civil investigative demand over sales and marketing practices, complicating the outlook as roughly half of regions show negative implant growth and a Medicare Advantage payer dispute persists. This combination of execution risk and regulatory scrutiny could weigh on shares in the near term unless management provides clarity.

News insight

CVRx, Inc. (CVRX) Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel Following Revenue Guidance Cut and Sales-Execution Disclosures

AI summary

Sentiment rationale

Key facts

Legal